(PharmaNewsWire.Com, July 06, 2017 ) Fungal infection is most common in those with weakened immune system or those who have foreign material, including medical devices in their body like an artificial joint or heart valve. Fungal infections are categorized under opportunistic and primary fungal infection. Opportunistic fungal infection targets weak immune patients and can be very aggressive, spreading quickly to other organs and often leading to death. While primary fungal infection can occur in people with a normal immune system. There are several types of antifungal medicines. They come in as creams, sprays, solutions, tablets designed to go into the vagina (pessaries) , shampoos, medicines to take by mouth, and injections. Most work by damaging the cell wall of the fungus, which causes the fungal cell to die.
The US is the largest market of anti-fungal drugs. It has the presence of the leading companies who specialize in anti-fungal drugs. The key factors driving growth of the anti-fungal market include rise in incidences of fungal infections in immuno-compromised patients, increase in number of cancer patients, rise in incidences of fungal infections in people suffering from AIDS, increase in spending on medicines, rise in sale of prescription drugs and many more.
However, market growth is hindered by the factors such as harsh side effects of drugs, drug resistance, high cost of anti-fungal, and lack of new anti-fungal therapies. The major trends featuring the market include increase in development of new drugs, flourishing public-private partnership in pharmaceutical industry, and growing awareness.
The report offers an in-depth analysis of the "Global Anti-Fungal Market" with special focus on invasive anti-fungal segment. It covers the regional and global aspects of the market. The top notch players in the market exhibit a very close competition. The report profiles JNJ, Novartis, Pfizer, and Merck & Co.
Table of Contents 1. Market Overview 2. Global Antifungal Market 3. Global Invasive Antifungal Market 4. Regional Anti-Fungal Market Analysis 5. Market Dynamics 6. Competitive Landscape 7. Company Profiles 7.1 Johnson & Johnson 7.1.1 Business Overview 7.1.2 Financial Overview 7.1.3 Business Strategies 7.2 Novartis AG 7.2.1 Business Overview 7.2.2 Financial Overview 7.2.3 Business Strategies 7.3 Pfizer Inc. 7.3.1 Business Overview 7.3.2 Financial Overview 7.3.3 Business Strategies 7.4 Merck & Co. Inc. 7.4.1 Business Overview 7.4.2 Financial Overview 7.4.3 Business Strategies Inquire for Report at http://www.reportsweb.com/inquiry&RW0001532595/buying
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
